Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 601–700 of 1,000

Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker
Vittos, O., Toana, B., Vittos, A., & Moldoveanu, E. (2012) · Biomarkers · doi:10.3109/1354750x.2012.664170 · Cited by 56
Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease
Gotto, A. M. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.059 · Cited by 56
Persistent Changes in Interleukin-6 and Lower Extremity Function Following Hip Fracture
Miller, R. R., Cappola, A. R., Shardell, M. D., Hawkes, W., Yu-Yahiro, J. A., Hebel, J. R., & Magaziner, J. S. (2006) · The Journals of Gerontology Series A · doi:10.1093/gerona/61.10.1053 · Cited by 56
Surrogate markers for atherosclerotic disease
Sankatsing, R. R., de Groot, E., Jukema, J. W., de Feyter, P. J., Pennell, D. J., Schoenhagen, P., Nissen, S. E., Stroes, E. S. G., & Kastelein, J. J. P. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000174400.68938.f6 · Cited by 55
Endothelial Cell Apoptosis is Responsible for the Formation of Coronary Thrombotic Atherosclerotic Plaques
Xu, F., Sun, Y., Chen, Y., Sun, Y., Li, R., Liu, C., Zhang, C., Wang, R., & Zhang, Y. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.218.25 · Cited by 55
Macrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Stöger, J. L., Goossens, P., & de Winther, M. P. J. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110790886983 · Cited by 54
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial
Sever, P., Poulter, N. R., Chang, C., Hingorani, A. D., Thom, S., Hughes, A. D., Welsh, P. I., Sattar, N. A., & on behalf of the ASCOT Investigators (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr262 · Cited by 56
CD40/CD40L and Related Signaling Pathways in Cardiovascular Health and Disease—The Pros and Cons for Cardioprotection
Daub, S., Lutgens, E., Münzel, T. F., & Daiber, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228533 · Cited by 56
Prognostic role of C‐reactive protein in very old patients with acute ischaemic stroke
Masotti, L., Ceccarelli, E., Forconi, S., & Cappelli, R. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01514.x · Cited by 55
Biomarcadores en la medicina cardiovascular
Martı́n-Ventura, J. L., Blanco‐Colio, L. M., Tuñón, J., Muñoz‐García, B., Madrigal‐Matute, J., Moreno, J. A., de Céniga, M. V., & Egido, J. (2009) · Revista Española de Cardiología · doi:10.1016/s0300-8932(09)71335-1 · Cited by 55
Statins in the treatment of chronic heart failure: Biological and clinical considerations
van der Harst, P., Voors, A. A., van Gilst, W. H., Böhm, M., & VANVELDHUISEN, D. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.04.011 · Cited by 55
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
D’Ugo, E., Libby, P., & De Caterina, R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0246 · Cited by 54
Relationship Between Inflammation and Benefits of Early High-Dose Rosuvastatin on Contrast-Induced Nephropathy in Patients With Acute Coronary Syndrome
Toso, A., Leoncini, M., Maioli, M., Tropeano, F., Vincenzo, E. D., Villani, S., & Bellandi, F. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.023 · Cited by 54
"Anti-Inflammatory" Drugs and Their Effects on Type 2 Diabetes
Deans, K. A., & Sattar, N. A. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.18 · Cited by 53
C-Reactive protein predicts severity, progression, and prognosis of asymptomatic aortic valve stenosis
Imai, K., Okura, H., Kume, T., Yamada, R., Miyamoto, Y., Kawamoto, T., Watanabe, N., Neishi, Y., Toyota, E., & Yoshida, K. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.04.011 · Cited by 54
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, open-label, dose-titration study in korean patients with hypercholesterolemia
Lee, S., Chung, N., Kwan, J., Kim, D. I., Kim, W. H., Kim, C. J., Kim, H. S., Park, S. H., Seo, H. S., & Shin, D. G. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.002 · Cited by 54
HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol
Kleemann, R., & Kooistra, T. (2005) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/156800605774962077 · Cited by 54
The role of statins in clinical medicine -LDL - cholesterol lowering and beyond
Rutishauser, J. (2006) · Swiss Medical Weekly · doi:10.4414/smw.2006.11170 · Cited by 53
Biochemical markers in acute coronary syndrome
Ramasamy, I. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.003 · Cited by 53
Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients
Roman, R. M., Camargo, P. V. S., Borges, F. K., Rossini, A. P. W., & Polanczyk, C. A. (2010) · Coronary Artery Disease · doi:10.1097/mca.0b013e328333f50d · Cited by 52
Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow
Eccles, K. A., Sowden, H., Porter, K. E., Parkin, S. M., Homer‐Vanniasinkam, S., & Graham, A. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.12.018 · Cited by 53
Statin Use and Hospitalization in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study in Taiwan
Huang, C., Chan, W., Chen, Y., Chen, T., Chou, K., Lin, S., Chen, J., & Leu, H. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.08.010 · Cited by 54
Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease
Signorelli, S. S., Anzaldi, M., Libra, M., Navolanic, P. M., Malaponte, G., Mangano, K., Quattrocchi, C., Marco, R. D., Fiore, V., & Neri, S. (2016) · Angiology · doi:10.1177/0003319716633339 · Cited by 53
Statin Treatment Is Not Associated With Consistent Alterations in Inflammatory Status of Carotid Atherosclerotic Plaques
Verhoeven, B. A. N., Moll, F. L., Koekkoek, J. A. F., van der Wal, A. C., de Kleijn, D. P. V., de Vries, J. P. M., Verheijen, J. H., Velema, E., Busser, E., Schoneveld, A. H., et al. (2006) · Stroke · doi:10.1161/01.str.0000231685.82795.e5 · Cited by 53
Gender differences in the association between C-reactive protein, lung function impairment, and COPD.
Ólafsdóttir, I. S., Gíslason, Þ., Þjóðleifsson, B., Ólafsson, Í., Gíslason, D., Jögi, R., & Janson, C. (2007) · Europe PMC (PubMed Central) · Cited by 53
Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography
Açıkel, S., Müderrisoğlu, H., Yı́ldı́rı́r, A., Aydınalp, A., Sade, L. E., Bayraktar, N., Bal, U. A., & Özin, B. (2010) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834014a4 · Cited by 52
Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women
Pöyhönen‐Alho, M., Manhem, K., Katzman, P., Kibarskis, A., Antikaínen, R., Erkkola, R. U., Tuomilehto, J. O., Ebeling, P. E., & Kaaja, R. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e328311cf37 · Cited by 51
Inflammatory biomarkers and coronary heart disease: from bench to bedside and back
Biasillo, G., Leo, M., Bona, R. D., & Biasucci, L. M. (2010) · Internal and Emergency Medicine · doi:10.1007/s11739-010-0361-1 · Cited by 53
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN)
Nicholls, S. J., Borgman, M., Nissen, S. E., Raichlen, J. S., Ballantyne, C. M., Barter, P. J., Chapman, M. J., Erbel, R. M., & Libby, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.570746 · Cited by 54
Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects
Patterson, K. A., Zhang, X., Wrobleski, S. K., Hawley, A. E., Lawrence, D. A., Wakefield, T. W., Myers, D. D., & Diaz, J. A. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.12.006 · Cited by 52
Preprocedural C-Reactive Protein Predicts Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-elevation Myocardial Infarction a systematic meta-analysis
Mincu, R., Jánosi, R. A., Vinereanu, D., Rassaf, T., & Totzeck, M. (2017) · Scientific Reports · doi:10.1038/srep41530 · Cited by 54
Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease
Ravi, S., Schuck, R. N., Hilliard, E., Lee, C. R., Dai, X., Lenhart, K. C., Willis, M. S., Jensen, B. C., Stouffer, G. A., Patterson, C., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.08.006 · Cited by 52
CD40L controls obesity-associated vascular inflammation, oxidative stress, and endothelial dysfunction in high fat diet-treated and db/db mice
Steven, S., Dib, M., Hausding, M., Kashani, F., Oelze, M. W., Kröller‐Schön, S., Hanf, A., Daub, S., Roohani, S., Gramlich, Y., et al. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx197 · Cited by 55
D‐Dimer and Inflammatory Markers as Predictors of Functional Decline in Men and Women with and without Peripheral Arterial Disease
McDermott, M. M., Ferrucci, L., Liu, K., Criqui, M. H., Greenland, P., Green, D., Guralnik, J. M., Ridker, P. M., Taylor, L. M., Rifai, N., et al. (2005) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53510.x · Cited by 52
Self-citation
The Role of Inflammation in Early and Late Venous Thrombosis: Are There Clinical Implications?
Wakefield, T. W., & Henke, P. K. (2005) · Seminars in Vascular Surgery · doi:10.1053/j.semvascsurg.2005.05.003 · Cited by 52
The kidney disease wasting: Inflammation, oxidative stress, and diet‐gene interaction
Kalantar‐Zadeh, K., & Balakrishnan, V. S. (2006) · Hemodialysis International · doi:10.1111/j.1542-4758.2006.00124.x · Cited by 52
Monomeric C-Reactive Protein in Atherosclerotic Cardiovascular Disease: Advances and Perspectives
Melnikov, I., Kozlov, S. G., Saburova, O., Avtaeva, Y., Guria, K. G., & Ахнафович, Г. З. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032079 · Cited by 56
Characterization of the Novel P-Selectin Inhibitor PSI-697 [2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] Quinoline-4-carboxylic acid] in Vitro and in Rodent Models of Vascular Inflammation and Thrombosis
Bedard, P. W., Clerin, V. M., Sushkova, N., Tchernychev, B., Antrilli, T. M., Resmini, C., Keith, J. C., Hennan, J. K., Kaila, N., DeBernardo, S., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.128124 · Cited by 51
Insights into atherosclerosis from invasive and non-invasive imaging studies: Should we treat subclinical atherosclerosis?
Santos, R. D., & Nasir, K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.12.017 · Cited by 50
C-Reactive Protein Stimulates Myeloperoxidase Release from Polymorphonuclear Cells and Monocytes: Implications for Acute Coronary Syndromes
Singh, U. S., Devaraj, S., & Jialal, I. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.109207 · Cited by 50
A comparative study of biomarkers for risk prediction in acute coronary syndrome—Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study
Kaski, J. C., Fernandez-Berges, D. J., Consuegra‐Sánchez, L., Fernández, J. M. C., García–Moll, X., Mostaza, J. M., Toro, R., González‐Juanatey, J. R., Guzmán, G., & Marrugat, J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.026 · Cited by 51
MicroRNA Regulators of Anxiety and Metabolic Disorders
Meydan, C., Shenhar‐Tsarfaty, S., & Soreq, H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.07.001 · Cited by 52
Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration
Mendieta, G., Ben‐Aicha, S., Gutiérrez, M., Casaní, L., Aržanauskaitė, M., Carreras, F., Sabaté, M., Badimón, L., & Vilahur, G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.042 · Cited by 51
LDL-cholesterol lowering or HDL-cholesterol raising for cardiovascular prevention
Sirtori, C. R., & Fumagalli, R. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.10.024 · Cited by 50
CRP, IL-6 and endothelin-1 levels in patients undergoing coronary artery bypass grafting. Do preoperative inflammatory parameters predict early graft occlusion and late cardiovascular events?
HEDMAN, A. G., Larsson, P. T., Alam, M., Wallén, N. H., Nordlander, R., & Samad, B. A. (2006) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.09.004 · Cited by 51
Metformin and pioglitazone: effectively treating insulin resistance
Staels, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112732 · Cited by 51
Application of intravascular ultrasound in anti-atherosclerotic drug development
Nicholls, S. J., Sipahi, İ., Schoenhagen, P., Crowe, T., Tuzcu, E. M., & Nissen, S. E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2040 · Cited by 52
The Relationship Between C-Reactive Protein and Atherosclerosis Differs on the Basis of Body Mass Index
Gupta, N., de Lemos, J. A., Ayers, C. R., Abdullah, S. M., McGuire, D. K., & Khera, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.050 · Cited by 51
Biomarkers in Cardiovascular Medicine
Martı́n-Ventura, J. L., Blanco‐Colio, L. M., Tuñón, J., Muñoz‐García, B., Madrigal‐Matute, J., Moreno, J. A., de Céniga, M. V., & Egido, J. (2009) · Revista Española de Cardiología (English Edition) · doi:10.1016/s1885-5857(09)72232-7 · Cited by 50
CVD screening in low-risk, asymptomatic adults: clinical trials needed
Polonsky, T. S., & Greenland, P. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.114 · Cited by 50
Influence of pericoronary adipose tissue on local coronary atherosclerosis as assessed by a novel MDCT volumetric method
Maurovich‐Horvat, P., Kallianos, K. G., Engel, L., Szymonifka, J. D., Fox, C. S., Hoffmann, U., & Truong, Q. A. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.049 · Cited by 50
Investigation of cytokines, oxidative stress, metabolic, and inflammatory biomarkers after orange juice consumption by normal and overweight subjects
Dourado, G. K. Z. S., & Cesar, T. B. (2015) · Food & Nutrition Research · doi:10.3402/fnr.v59.28147 · Cited by 51
Low-Density Lipoprotein Cholesterol Reduction: The End Is More Important Than the Means
LaRosa, J. C. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.089 · Cited by 51
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 52
Platelet mitochondrial DNA methylation predicts future cardiovascular outcome in adults with overweight and obesity
Corsi, S., Iodice, S., Vigna, L., Çayır, A., Mathers, J. C., Bollati, V., & Byun, H. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00825-5 · Cited by 52
C-reactive protein predicts further ischemic events in transient ischemic attack patients
Purroy, F. F., Montaner, J., Molina, C. A., Delgado, P., Arenillas, J. F., Chacón, P. M., Quintana, M., & Álvarez‐Sabín, J. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00715.x · Cited by 50
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS)
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Livingstone, S. J., Thomason, M. J., Fuller, J., & on behalf of the CARDS Investigators (2005) · Diabetologia · doi:10.1007/s00125-005-0029-y · Cited by 50
DNA variants, plasma levels and variability of C-reactive protein in myocardial infarction survivors: results from the AIRGENE study
Kolz, M., Köenig, W., Müller‐Nurasyid, M., Andreani, M., Greven, S., Illig, T., Khuseyinova, N., Panagiotakos, D. B., Pershagen, G., Salomaa, V. V., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm442 · Cited by 52
The IDEAL Cholesterol
Cannon, C. P. (2005) · JAMA · doi:10.1001/jama.294.19.2492 · Cited by 50
Self-citation
Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness
Omer, S. B., Phadke, V. K., Bednarczyk, R. A., Chamberlain, A. T., Brosseau, J. L., & Orenstein, W. A. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv457 · Cited by 49
Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention
Ridker, P. M., MacFadyen, J. G., Glynn, R. J., & Chasman, D. I. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.110.959353 · Cited by 49
Self-citation
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
Athyros, V. G., Katsiki, N., Karagiannis, A. I., & Mikhailidis, D. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1053464 · Cited by 48
Inflammation may modulate IL-6 and C-reactive protein gene expression in the adipose tissue: the role of IL-6 cell membrane receptor
Memoli, B., Procino, A., Calabrò, P., Esposito, P. B., Grandaliano, G., Pertosa, G. B., Prete, M. D., Andreucci, M., Lillo, S. D., Ferulano, G. P., et al. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00697.2006 · Cited by 51
Concomitant Reduction of Low-Density Lipoprotein-Cholesterol and Biomarkers of Inflammation with Low-Dose Simvastatin Therapy in Patients with Type 1 Diabetes
Jialal, I., Miguelino, E., Griffen, S. C., & Devaraj, S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0453 · Cited by 50
Sex Differences in Inflammatory Markers and Health Status Among Young Adults With Acute Myocardial Infarction
Lu, Y., Zhou, S., Dreyer, R. P., Spatz, E. S., Geda, M. E., Lorenze, N. P., D’Onofrio, G., Lichtman, J. H., Spertus, J. A., Ridker, P. M., et al. (2017) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003470 · Cited by 51
Self-citation
The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient
Ong, H. T. (2005) · QJM · doi:10.1093/qjmed/hci093 · Cited by 49
Inflammation, Atherosclerosis, and Aspects of Insulin Action
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2312 · Cited by 48
Long-term weight maintenance and cardiovascular risk factors are not different following weight loss on carbohydrate-restricted diets high in either monounsaturated fat or protein in obese hyperinsulinaemic men and women
Keogh, J. B., Luscombe-Marsh, N. D., Noakes, M., Wittert, G. A., & Clifton, P. M. (2007) · British Journal of Nutrition · doi:10.1017/s0007114507252687 · Cited by 48
The Immunomodulatory Effects of Statins on Macrophages
Sheridan, A., Wheeler-Jones, C. P. D., & Gage, M. C. (2022) · Immuno · doi:10.3390/immuno2020021 · Cited by 48
Inflammation in coronary artery disease-clinical implications of novel HDL-cholesterol–related inflammatory parameters as predictors
Guo, X., & Ma, L. (2022) · Coronary Artery Disease · doi:10.1097/mca.0000000000001198 · Cited by 54
Pathophysiology, Diagnosis, and Management of Dyslipidemia
Gau, G. T., & Wright, R. S. (2006) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2006.03.001 · Cited by 49
Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin
Pesaro, A. E. P., Junior, C. V. S., Fernandes, J. L., Cavalcanti, A. B., Campos, A. H., Martins, H. S., Maranhão, R. C., de Lemos, J. A., de Souza, H. P., & Nicolau, J. C. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.01.062 · Cited by 48
Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer
Pastorino, U., Morelli, D., Leuzzi, G., Gisabella, M., Suatoni, P., Taverna, F., Bertocchi, E., Boeri, M., Sozzi, G., Cantarutti, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.020 · Cited by 48
Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy
Galiullina, L. F., Scheidt, H. A., Huster, D., Aganov, A. V., & Klochkov, V. V. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.12.013 · Cited by 49
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Atherogenic Lipid/Lipoprotein, Apolipoprotein, and Inflammatory Parameters in Patients With Elevated High-Sensitivity C-Reactive Protein (from the ANCHOR Study)
Miller, M. J., Ballantyne, C. M., Bays, H. E., Granowitz, C. B., Doyle, R. T., Juliano, R. A., & Philip, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.057 · Cited by 49
Anti-Inflammatory Agents and Antioxidants as a Possible “Third Great Wave” in Cardiovascular Secondary Prevention
Bhatt, D. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.002 · Cited by 48
Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach
Möckel, M. M., Müller, R., Vollert, J. O., Müller, C., Danne, O., Gareis, R., Störk, T. V., Dietz, R., & Köenig, W. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0540-x · Cited by 48
Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe
Daskalopoulou, S. S., & Mikhailidis, D. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x89856 · Cited by 48
Plant-Based Diets and Lipid, Lipoprotein, and Inflammatory Biomarkers of Cardiovascular Disease: A Review of Observational and Interventional Studies
Elliott, P. S., Kharaty, S. S., & Phillips, C. M. (2022) · Nutrients · doi:10.3390/nu14245371 · Cited by 53
Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers
Arsenault, B. J., Barter, P. J., DeMicco, D. A., Bao, W., Preston, G. M., LaRosa, J. C., Grundy, S. M., DEEDWANIA, P. C., Greten, H., WENGER, N. K., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114519 · Cited by 48
Electronegative Low-Density Lipoprotein Increases C-Reactive Protein Expression in Vascular Endothelial Cells through the LOX-1 Receptor
Chu, C., Wang, Y.-C., Lu, L., Walton, B. L., Yilmaz, H. R., Huang, R., Sawamura, T., Dixon, R. A. F., Lai, W., Chen, C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070533 · Cited by 47
High-Sensitive C-Reactive Protein: Universal Prognostic and Causative Biomarker in Heart Disease?
Rietzschel, E. R., & Buyzere, M. D. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.11.108 · Cited by 49
Significant association between Helicobacter pylori infection and serum C-reactive protein
Ishida, Y., Suzuki, K. A. O., Taki, K., Niwa, T., Kurotsuchi, S., Ando, H., Iwase, A., Nishio, K., Wakai, K., Ito, Y., et al. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.224 · Cited by 47
Promoting general health during androgen deprivation therapy (ADT): A rapid 10-step review for your patients
Moyad, M. A. (2005) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2005.03.018 · Cited by 47
Prevention of Atherosclerosis in Overweight/Obese Patients - In Need of Novel Multi-Targeted Approaches -
Lim, S. K., Després, J., & Koh, K. K. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1240 · Cited by 48
Alirocumab in Acute Myocardial Infarction: Results From the Virginia Commonwealth University Alirocumab Response Trial (VCU-AlirocRT)
Trankle, C. R., Wohlford, G. F., Buckley, L. F., Kadariya, D., Ravindra, K., Markley, R., Park, T. S., Potere, N., Tassell, B. W. V., & Abbate, A. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000706 · Cited by 47
Metabolic Inflammation in Obesity—At the Crossroads between Fatty Acid and Cholesterol Metabolism
Curley, S., Gall, J., Byrne, R., Yvan‐Charvet, L., & McGillicuddy, F. C. (2020) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900482 · Cited by 50
Statin Therapy Increases Carotid Plaque Echogenicity in Hypercholesterolemic Patients
Yamagami, H., Sakaguchi, M., Furukado, S., Hoshi, T., Abe, Y., Hougaku, H., Hori, M., & Kitagawa, K. (2008) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2008.01.019 · Cited by 47
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) trial
Rouleau, J. L. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.014 · Cited by 47
Atherosclerosis, cholesterol, nutrition, and statins--a critical review.
Gebbers, J. (2007) · Europe PMC (PubMed Central) · Cited by 47
Statin Treatment and Diabetes Affect Myeloperoxidase Activity in Maintenance Hemodialysis Patients
Stenvinkel, P., Accent]guez-Ayala, E. R. A., Massy, Z. A., Qureshi, A. R., Barany, P. F., Diaeresis]m, B. F., Heimbürger, O., Lindholm, B., & Alvestrand, A. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01281005 · Cited by 47
Inflammatory Marker Mania in Chronic Kidney Disease
Kalantar‐Zadeh, K. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02750707 · Cited by 47
Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events
Arca, M., & Gaspardone, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00004 · Cited by 47
Dietary glycemic index, glycemic load, and chronic disease: an umbrella review of meta-analyses of prospective cohort studies
Jayedi, A., Soltani, S., Jenkins, D. J. A., Sievenpiper, J. L., & Shab‐Bidar, S. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1854168 · Cited by 46
Impact of Cholesterol Metabolism on Coronary Plaque Vulnerability of Target Vessels
Nasu, K., Terashima, M., Habara, M., Ko, E., Ito, T., Yokota, D., Ishizuka, S., Kurita, T., Kimura, M., Kinoshita, Y., et al. (2013) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.02.018 · Cited by 46
High-Sensitivity C-Reactive Protein as a Predictor of All-Cause Mortality: Implications for Research and Patient Care
Ridker, P. M. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.099465 · Cited by 47
Self-citation
Elevated Inflammation Markers in Pheochromocytoma Compared to Other Forms of Hypertension
Zelinka, T., Petrák, O., Štrauch, B., Holaj, R., Kvasnička, J., Mazoch, J., Pacák, K., & Widimsky, J., Jr. (2007) · NeuroImmunoModulation · doi:10.1159/000107289 · Cited by 46
Comparison of Effectiveness of Rosuvastatin Versus Atorvastatin on the Achievement of Combined C-Reactive Protein (<2 mg/L) and Low-Density Lipoprotein Cholesterol (<70 mg/dl) Targets in Patients With Type 2 Diabetes Mellitus (from the ANDROMEDA Study)
Betteridge, D. J., Gibson, M., & Sager, P. T. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.044 · Cited by 46
Effects of Pitavastatin on Lipid Profiles and High-Sensitivity CRP in Japanese Subjects with Hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigatars
Koshiyama, H., Taniguchi, A., Tanaka, K., Kagimoto, S., Fujioka, Y., Hirata, K., Nakamura, Y., Iwakura, A., Hara, K., Yamamoto, T., et al. (2008) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.e581 · Cited by 46
C-Reactive Protein and Cardiovascular Disease Risk: Still an Unknown Quantity?
Smith, G. D., Timpson, N. J., & Lawlor, D. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00130 · Cited by 46

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks